Long-Term Outcome of 335 Adult Patients Receiving Different Schedules of Imatinib and Chemotherapy as Front-Line Treatment for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)

被引：0

作者：

Pfeifer, Heike ^{[1
]}

Goekbuget, Nicola ^{[2
]}

Voelp, Christian ^{[1
]}

Huettmann, Andreas ^{[3
]}

Luebbert, Michael ^{[4
]}

Stuhlmann, Reingard ^{[5
]}

Dengler, Julanta ^{[6
]}

Kreuzer, Karl-Anton ^{[7
]}

Beck, Joachim ^{[8
]}

Stelljes, Matthias ^{[9
]}

Schmid, Mathias ^{[10
]}

Wassmann, B. ^{[1
]}

Leimer, Lothar ^{[11
]}

Spiekermann, Karsten ^{[12
]}

Terwey, Theis E. ^{[13
]}

Schaefer-Eckart, K. ^{[14
]}

Ditz, D. ^{[15
]}

Lindemann, H. ^{[16
]}

Morgner, A. ^{[17
]}

Schaich, Markus ^{[18
]}

Burmeister, Thomas ^{[19
]}

Binckebanck, A. ^{[1
]}

Hoelzer, Dieter

Ottmann, Oliver G. ^{[1
]}

机构：

[1] Goethe Univ Frankfurt, Dept Med, Frankfurt, Germany

[2] Goethe Univ Hosp, Dept Med, Frankfurt, Germany

[3] Univ Hosp, D-45122 Essen, Germany

[4] Univ Hosp Freiburg, Dept Hematol & Oncol, Freiburg, Germany

[5] Asklepios Klin St Georg, Hamburg, Germany

[6] Univ Heidelberg, Dept Hematol, Heidelberg, Germany

[7] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[8] Univ Hosp, Mainz, Germany

[9] Univ Munster, Munster, Germany

[10] Univ Hosp Ulm, Ulm, Germany

[11] Robert Bosch Krankenhaus, Stuttgart, Germany

[12] Univ Munich, Klinikum Grosshadern, Med Klin 3, D-8000 Munich, Germany

[13] Charite, D-13353 Berlin, Germany

[14] Klinikum Nurnberg, Dept Hematol, Med Klin 5, Nurnberg, Germany

[15] Univ Regensburg, Regensburg, Germany

[16] Katholisches Krankenhaus Hagen, Dresden, Germany

[17] Krankenhaus Kuchwald Chemnitz, Dresden, Germany

[18] Univ Klinikum Carl Gustav Carus, Dresden, Germany

[19] Univ Hosp Berlin, Charlie, Dept Hematol & Oncol, Berlin, Germany

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：79 / 79

页数：1

共 50 条

[31] Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00
Bassan, Renato
Rossi, Giuseppe
Pogliani, Enrico M.
Di Bona, Eros
Angelucci, Emanuele
Cavattoni, Irene
Lambertenghi-Deliliers, Giorgio
Mannelli, Francesco
Levis, Alessandro
Ciceri, Fabio
Mattei, Daniele
Borlenghi, Erika
Terruzzi, Elisabetta
Borghero, Carlo
Romani, Claudio
Spinelli, Orietta
Tosi, Manuela
Oldani, Elena
Intermesoli, Tamara
Rambaldi, Alessandro
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) : 3644 - 3652
[32] A randomized phase II study of single-agent imatinib versus chemotherapy therapy in elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) including analysis of resistance patterns
Pfeifer, H
Ottmann, OG
Goekbuget, N
Wunderle, L
Brueck, P
Giagounidis, A
Stelijes, M
Hochhaus, A
Gschaidineier, H
Hoelzer, D
Wassmann, B
BLOOD, 2005, 106 (11) : 519A - 519A
[33] Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL)
Wassmann, B
Pfeifer, H
Scheuring, U
Klein, SA
Gökbuget, N
Binckebanck, A
Martin, H
Gschaidmeier, H
Hoelzer, D
Ottmann, OG
LEUKEMIA, 2002, 16 (12) : 2358 - 2365
[34] Cost effectiveness of adding imatinib to chemotherapy in adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL):: An exploratory analysis for the UK
Botteman, M. F.
Tran, K. T.
Stephens, J. M.
VALUE IN HEALTH, 2006, 9 (06) : A289 - A289
[35] Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study
A Delannoy
E Delabesse
V Lhéritier
S Castaigne
F Rigal-Huguet
E Raffoux
F Garban
O Legrand
S Bologna
V Dubruille
P Turlure
O Reman
M Delain
F Isnard
D Coso
P Raby
A Buzyn
S Caillères
S Darre
C Fohrer
A Sonet
C Bilhou-Nabera
M-C Béné
H Dombret
P Berthaud
X Thomas
Leukemia, 2006, 20 : 1526 - 1532
[36] Cost-Effectiveness of Adding Imatinib to Chemotherapy in Adult Patients with Chromosom-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): A Canadian Perspective
El Ouagari, Khalid
Tran, Kimbach
Stephens, Jennifer
Botteman, Marc
BLOOD, 2008, 112 (11) : 837 - 837
[37] Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study
Delannoy, A.
Delabesse, E.
Lheritier, V.
Castaigne, S.
Rigal-Huguet, F.
Raffoux, E.
Garban, F.
Legrand, O.
Bologna, S.
Dubruille, V.
Turlure, P.
Reman, O.
Delain, M.
Isnard, F.
Coso, D.
Raby, P.
Buzyn, A.
Cailleres, S.
Darre, S.
Fohrer, C.
Sonet, A.
Bilhou-Nabera, C.
Bene, M-C
Dombret, H.
Berthaud, P.
Thomas, X.
LEUKEMIA, 2006, 20 (09) : 1526 - 1532
[38] Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment
U J Scheuring
H Pfeifer
B Wassmann
P Brück
B Gehrke
E K Petershofen
H Gschaidmeier
D Hoelzer
O G Ottmann
Leukemia, 2003, 17 : 1700 - 1706
[39] IMATINIB MAINTENANCE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE (PH plus ) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Kebriaei, P.
Chiattone, A.
Saliba, R.
Jones, D.
Anderlini, P.
Andersson, B.
Khouri, I
Worth, L.
Ravandi, F.
Thomas, D.
Kantarjian, H.
Hamerschlak, N.
Rodrigues, M.
de Lima, M.
Giralt, S.
Champlin, R.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S230 - S230
[40] Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment
Scheuring, UJ
Pfeifer, H
Wassmann, B
Brück, P
Gehrke, B
Petershofen, E
Gschaidmeier, H
Hoelzer, D
Ottmann, OG
LEUKEMIA, 2003, 17 (09) : 1700 - 1706

← 1 2 3 4 5 →